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The molecular targets of the vast majority of autoantibodies in systemic lupus erythematosus 
(SLE) are unknown. We set out to identify novel autoantibodies in SLE to improve diagnosis and 
identify subgroups of SLE individuals. 
Methods 
A baculovirus-insect cell expression system was used to create an advanced protein microarray 
with 1543 full-length human proteins expressed with a biotin carboxyl carrier protein (BCCP) 
folding tag, to enrich for correctly folded proteins. Sera from a discovery cohort of UK and US 
SLE individuals (n=186) and age/ethnicity matched controls (n=188) were assayed using the 
microarray to identify novel autoantibodies. Autoantibodies were confirmed in a validation 
cohort (91 SLE, 92 controls) and confounding rheumatic disease cohort (n=92). 
Results 
We confirmed 68 novel proteins as autoantigens in SLE and 11 previous autoantigens in both 
cohorts (FDR<0.05). Using hierarchical clustering and principal component analysis, we 
observed four subgroups of SLE individuals associated with four corresponding clusters of 
functionally linked autoantigens. Two clusters of novel autoantigens revealed distinctive 
networks of interacting proteins: SMAD2, SMAD5 and proteins linked to TGF-β signalling; and 
MyD88 and proteins involved in TLR signalling, apoptosis, NF-κB regulation and lymphocyte 
development. The autoantibody clusters were associated with different SLE manifestations 
(arthritis, renal and thrombocytopenia). A panel of 26 autoantibodies, derived by penalised 
multinomial logistic regression taking into account four SLE clusters, showed improved 
diagnostic accuracy compared to conventional antinuclear antibody and anti-dsDNA antibody 
assays. 
Conclusions 
These data suggest that the novel SLE autoantibody clusters may be of prognostic utility for 
predicting organ involvement in SLE patients and for stratifying SLE patients for specific 
therapies. 
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Although first described in 1957, anti-nuclear antibodies (ANA) and anti-double-stranded DNA 
(dsDNA) antibody assays remain the primary diagnostic tests for systemic lupus erythematosus 
(SLE) [1, 2]. Following the development of assays for extractable nuclear antigens (ENA) Ro, 
La, Sm and U1-RNP, there have been no significant improvements in diagnostic assays for SLE 
for many years [3]. In contrast, the identification of citrullinated proteins as autoantigen epitopes 
in rheumatoid arthritis (RA) led to a marked improvement in RA diagnostic tests with the 
development of anti-cyclic citrullinated peptide (CCP) assays. Although numerous SLE-
associated autoantibodies have been described [4], they have not significantly improved upon the 
diagnostic and biomarker abilities of conventional ANA, dsDNA and ENA tests, and in many 
cases the true molecular targets remain undefined. Initial protein microarrays used to detect 
autoantibodies in SLE sera were largely based on existing autoantigens, but have identified 
several glomerular proteins and serum factors including B cell-activating factor (BAFF) as SLE 
autoantigens [5-10]. Microarrays utilising large scale de novo synthesis of thousands of proteins 
have detected autoantibodies in cancer and other diseases [11, 12], but only identified a single 
SLE autoantigen [13]. Older protein microarrays may have failed to identify autoantibodies due 
to poor protein conformation caused by misfolding or lack of post-translational modification. 
 We used a novel protein microarray utilising 1543 distinct proteins chosen from multiple 
functional and disease pathways, to identify novel autoantigens in SLE.  Our aim was to identify 
previously undiscovered autoantibodies that might act as SLE biomarkers to improve diagnostic 
(and potentially prognostic) performance over existing clinical assays and to determine whether 
subgroups of SLE patients with different autoantibody repertoires existed. Full-length human 
proteins bound to the microarray were expressed in a baculovirus-insect cell expression system 
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with a biotin carboxyl carrier protein (BCCP) folding tag. The BCCP tag enriches for correctly 
folded proteins, conserving protein epitopes in their native conformation, which may be 
necessary for high affinity antibody binding (Figure 1A) [14]. In this study, we used this newer 





2. Materials and Methods 
2.1. Study population 
Serum samples from SLE individuals were collected from multiple UK institutions and USA 
(Seralabs). Serum samples from age/ethnicity matched controls for UK individuals were 
obtained from the TwinsUK resource (part of the National Institute for Health Research (NIHR) 
BioResource) and for USA individuals from Seralabs. SLE and control samples were randomly 
assigned 2:1 to the Discovery cohort (186 SLE and 188 controls) and the Validation cohort (91 
SLE and 92 controls). SLE patients were almost all female reflecting the sexual dimorphism of 
SLE, while healthy controls were exclusively female. All SLE patients fulfilled the 1997 revised 
American College of Rheumatology (ACR) criteria for classification of SLE. The validation 
cohort was compared with a Confounding/ interfering disease cohort included patients with the 
following conditions: systemic sclerosis (n=12), primary Sjögren’s syndrome (n=6), 
polymyositis (n=3) and mixed connective tissue disease (n=3) sourced from USA (Seralabs), and 
rheumatoid arthritis (RA) (n=68) obtained from multiple UK institutions. RA patients fulfilled 
the 2010 ACR-EULAR (European League against Rheumatism) criteria for diagnosis of RA. 
Ethical approval was granted by the Independent Investigational Review Board Inc. (4/16/2008) 
and the UK National Research Ethics Service London (reference numbers MREC98/2/06, 
06/MRE02/9 and 07/H0718/49). 
 
2.2. Protein microarray 
Protein microarray assay using the Discovery Array v3.0 protein microarray is described in the 





2.3. Serum autoantibody measurement 
Anti-dsDNA and ANA titres were measured in all serum samples by ELISA (QUANTA Lite cat 
no. 704650 & 708750; Inova Diagnostics, San Diego, USA), according to the manufacturer’s 
instructions. ANA results were classified as negative (<20 units), moderate positive (20-60 units) 
or strong positive (>60 units) using thresholds determined by the manufacturer. Anti-dsDNA 
samples were classified as negative (<30 IU/mL), borderline (30-75 IU/mL), positive (>75 
IU/mL) according to the manufacturer’s protocol. ANA and dsDNA results were not based on 
historical case record results. 
 
2.4. Statistical analysis 
Statistical analysis, protein-protein interaction analysis, genotyping, HLA imputation and 
analysis, and predictive models are described in detail in the Supplementary Methods. The 




3. Results  
3.1. Identification of novel SLE-associated autoantigens by microarray 
Serum samples from a discovery cohort of 186 SLE patients and 188 age/ethnicity matched 
healthy controls (Table S1) were analysed for IgG autoantibody levels against 1543 correctly 
folded, full-length human proteins using a custom protein microarray (Oxford Gene Technology, 
UK) (Figure 1A). Samples were assayed by ELISA for ANA and anti-dsDNA antibodies for 
comparison. Normalised autoantibody levels were compared between SLE individuals and 
healthy controls in the discovery cohort, using a linear regression model adjusting for age, 
gender, ethnicity and country. A total of 226 autoantibodies, which were increased in the SLE 
individuals compared to controls in the discovery cohort at FDR-corrected P<0.05, were 
investigated in a validation cohort of 91 SLE individuals and 92 age/ethnicity matched controls. 
Demographics for the discovery and validation cohorts are shown in Table S1. Of 226 
autoantigens observed in the discovery cohort, a total of 79 autoantibodies were also 
significantly increased in SLE individuals in the validation cohort at FDR<0.05 (Figure 1C, 
Table S2). The well-known SLE autoantigens TROVE2 (Ro60) and SSB (La) showed the most 
significant difference between SLE and control groups in both cohorts. The array validated a 
further nine previously reported SLE autoantigens (Figure 1D, Table S2). A total of 68 novel 
autoantigens were validated by the microarray, with the most statistically significant four novel 
autoantibodies shown in Figure 1E. 
A post-validation meta-analysis was performed using a regression model adjusting for 
age, gender, ethnicity and country. Suggestive evidence at FDRmeta<0.01 was found for a further 
41 autoantibodies (Table S3), of which 38 were novel. Nine of the validated autoantigens have 
been shown to be implicated in SLE pathogenesis through immunological studies, but were not 
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previously known to be autoantigens: CREB1, ZAP70, VAV1, PPP2CB, IRF4, IRF5, EGR2, 
PPP2R5A and LYN [15-19], while TEK (Tie2 receptor) was identified in the meta-analysis [20]. 
Five novel autoantigens are the products of SLE susceptibility genes: IRF5, LYN, PIK3C3, 
NFKBIA and DNAJA1 [21-25]. In summary, 26 of 120 autoantigens (79 validated and 41 
identified in the meta-analysis) have a previously identified link to SLE, either as known 
autoantibody targets or directly implicated in SLE pathogenesis. 
 In a secondary analysis of the discovery cohort, autoantibodies from the array were 
ranked by positivity in SLE patients, defined as autoantibody levels >2 SD of the control 
population, and tested for statistical significance using Fisher’s exact test, corrected for multiple 
testing. Autoantibodies with FDR-corrected P<0.05 were analysed for positivity in the validation 
cohort. A total of 60 autoantibodies showed a significant increase in antibody positivity in both 
discovery and validation cohorts (Figure 2A). The most prevalent autoantibodies were the known 
SLE autoantigens Ro60 (overall prevalence 37.5%), SSB/La (35.4%), HNRNPA2B1 (29.6%) 
and PSME3/Ki (23.8%). The most prevalent novel autoantibodies were LIN28A (22.4%), 
IGF2BP3 (21.7%) and HNRNPUL1 (21.3%). SLE patients tended to be simultaneously positive 
for multiple autoantibodies in contrast to the control group (Kruskal-Wallis test with post-hoc 
Nemenyi test, P<2×10
−16
) and confounding disease group (P=6.7×10
−9
), with some individuals 
producing antibodies against over 60 antigens (Figure 2B). 
 
3.2. SLE autoantibodies cluster into four distinct subgroups 
Since we observed that groups of autoantibodies showed strong cross-correlation, we performed 
unsupervised hierarchical clustering of autoantibody levels in SLE individuals in the discovery 
cohort and compared with clustering of the validation cohort. In both the discovery and 
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validation cohorts, SLE individuals clustered into four subgroups, designated: SLE 1a, 1b, 2 and 
3 (Figure 3A).  Each subgroup was associated with four distinct clusters of autoantibodies 
(Clusters 1a, 1b, 2 and 3). We have applied this nomenclature based on functional 
characterization of the autoantigen clusters (see below). SLE subgroup 1a individuals were 
characterised by being strongly anti-Ro60 and anti-La positive. SLE subgroup 2 showed the 
broadest range of autoantibody positivity, SLE subgroup 3 were mainly positive for cluster 3 
antibodies, while SLE group 1b showed a mixed pattern. The existence of these groupings is 
borne out in a condensed subspace heatmap of the SLE subgroups which also shows the striking 
similarity in antibody patterns across the four patient clusters between discovery and validation 
cohorts (Figure S1). 
Cross-correlation of the autoantigens (Figure 3B) revealed strong internal correlation 
within each antibody cluster, confirming existence of four autoantibody clusters, with certain 
autoantigens (e.g. RQCD1, SUB1) showing a tendency to inverse correlation with autoantibodies 
from other clusters. The existence of the autoantibody subgroups of response was confirmed by 
clustering of all four SLE subgroups when data were re-analysed with inclusion of controls 
(n=280) using principal component analysis (PCA) (Figure 4A, Movie S1 and Figure S2). PCA 
showed delineation between SLE patient clusters 1a, 2 and 3 on PC2 and PC3, with PC1 aiding 
delineation between control and SLE individuals as well as SLE cluster 1b. Component loadings 





3.3. Autoantibody cluster-defined SLE subgroups show different disease characteristics 
To probe whether the autoantibody clusters were linked to differential SLE phenotype, we 
compared ANA and dsDNA antibody levels in the four SLE subgroups. SLE group 1a, whose 
individuals are strongly Ro60 and La positive, showed very high levels of ANA positivity 
(P<0.01, Kruskal-Wallis test), while SLE group 2 showed the highest levels of anti-dsDNA 
antibodies (P<0.01) (Figure 4C). Groups 1b and 3 showed significantly lower levels of both 
ANA and dsDNA antibodies, consistent with these groups being distinct entities. Furthermore, 
analysis of ANA negative individuals (at the time of the assay) showed that these were almost 





 test) (Figure 4D). Similarly, subgroups 1b and 3 made up 69% of dsDNA 
negative SLE individuals (P=8.4×10
−5
). ANA and dsDNA antibody levels were measured by 
ELISA on the same serum samples as the microarray assay, and were not based on patient 
clinical records. This suggests that the novel autoantibodies from cluster 1b and 3 are particularly 
important for diagnosing SLE patients with intermittently negative ANA/dsDNA antibodies for 
whom existing diagnostic tests may be unreliable.  
SLE subphenotype clinical data available on 184 UK SLE individuals was analysed for 
trends in autoantibody positivity across autoantibody clusters. While some subphenotype 
characteristics such as skin rash were similar across all four clusters, autoantibody clusters 
showed specificity for presence or absence of arthritis (P=0.00063 for interaction between cluster 
and subphenotype by two-way ANOVA), pulmonary (P=0.0059) and neurological involvement 
(P=0.038) (Figure 4E), suggesting that there are subphenotype differences between the 
autoantibody clusters. Group 2 autoantibody positivity was higher in the presence of arthritis, 
while group 1A was lower. Renal involvement was associated with IGF2BP3 positivity 
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(P=0.015) and higher cluster 1B positivity. CARHSP1 positivity showed particularly strong 
association with the presence of thrombocytopenia (P=0.00028). TWIST2 positivity was 
associated with oral ulceration (P=0.016). 
Medication usage data was available on 234 SLE individuals from both UK and US 
cohorts. No difference was seen for the majority of immunosuppressive medications between 
SLE clusters, however, SLE3 individuals showed lower prednisolone usage (P=0.0044, Fisher’s 
exact test) and higher warfarin usage (P=0.0078). This raises the possibility that the cluster 3 
autoantibodies might be associated with anti-phospholipid syndrome. 
 
3.4. SLE autoantigen clusters associate with functional protein-protein interaction 
networks 
To examine whether the clusters of autoantigens identified associated with different SLE 
subgroups showed themes of molecular or functional categorisation, each cluster of autoantigens 
was investigated using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) 
database, and cross-referenced against Ingenuity Pathway Analysis and the PANTHER (protein 
annotation through evolutionary relationship) classification system. The 79 validated 
autoantigens were insufficient for meaningful pathway analysis, so were supplemented with 41 
putative autoantigens identified by post-validation meta-analysis. Protein interaction networks 
identified using STRING were discernible in cluster 2 and cluster 3 autoantigens. In cluster 2, 
the largest network of interacting proteins was centred around SMAD2, SMAD5 and included 
proteins associated with TGF-β, Wnt and bone morphogenic protein (BMP) signalling such as 
PPP2CB, ID2, TWIST2, CSNK2A1 and CSNK2A2 (Figure 5A). In cluster 3, a protein network 
of genes involved in toll-like receptor (TLR) signalling and NF-κB activation including MYD88, 
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BIRC3 (cIAP-2), NFKBIA (IB), MAP3K7 (TAK1) and MAP3K14 (NIK) was observed, 
interlinked with genes involved in apoptosis regulation such as BIRC3 (cIAP-2), ANXA1 
(Annexin A1), CASP9 (caspase-9), ZMYND11 and BCL2A1 (Figure 5B). The cluster 3 network 
also incorporated key proteins involved in lymphocyte differentiation such as VAV1, EGR2, 
ZAP70 and SH2B1. STRING identified TGFBR1 (TGF-β receptor 1) and RELA (NF-κB p65) as 
predicted functional nodes for clusters 2 and 3 respectively (prediction score 0.999). The 
functional themes of the autoantigen clusters are summarised in Figure 5C. 
 
3.5. Improved diagnostic accuracy of expanded autoantibody panels 
Elastic net regularised logistic regression was employed as a variable selection method to 
identify an optimal autoantibody panel for SLE diagnosis. 10-fold cross-validation (using the 
discovery cohort) was used to select L1-L2 parameter α and shrinkage parameter λ (Figure S4). 
The optimal penalized binomial logistic regression model (α=0.7, λ1se=0.00764), employing 17 
autoantibodies (Table S4), was tested on the Validation cohort using Receiver Operating 
Characteristic (ROC) curve analysis (Figure 6A). The performance of autoantibody models at 
discriminating SLE individuals from a non-SLE group including both healthy controls and 
confounding group individuals (mostly RA), to mimic the real-world situation of a typical 
rheumatology clinic. Low level ANA positivity is commonly observed in healthy individuals 
[26], other autoimmune diseases or pregnant individuals. Thus in clinical practice ANA performs 
more poorly, since it is significantly less specific than dsDNA antibodies at lower titres. The 
elastic net binomial regression model showed improved sensitivity (59.3%) at high specificity 
(90%) (Figure 6A,B), compared to standard ANA (37.0%) and dsDNA antibody (38.6%) assays 
and combined ANA+dsDNA regression model (47.8%). However, this model did not reflect the 
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different patient clusters as well as other autoantibodies (Figure S5). We hypothesized that a 
biomarker model, which exploited the distinct clustering of autoantibodies in SLE individuals, 
could be superior to binomial regression models. First, we used elastic net regularized 
multinomial logistic regression for variable selection to narrow the autoantibodies to a set of 26 
autoantibodies which optimally identified the four SLE clusters in the discovery cohort (Figure 
6C). This reduced set of 26 autoantibodies was trained using penalised mixture discriminant 
analysis (MDA) [27, 28] to enable separation of clustered data, specifying one control cluster 
and four SLE clusters. The MDA model showed superior diagnostic classification compared to 
the binomial elastic net regression model, with a sensitivity of 67.0% at specificity 90%. 
Addition of ANA and dsDNA antibodies to the MDA model did not improve prediction (Figure 
S6). The improvement in the MDA model compared to the elastic net binomial regression model 
is likely to be due to the non-linear decision boundary (Figure S7), which delineates four 
separate SLE clusters from healthy controls, in both discovery and validation cohorts. The panel 
of 26 autoantibodies was able to delineate different patterns of subphenotype and organ 
involvement (Figure S3). 
 
4. Discussion 
Using a novel protein microarray design optimised to enhance presentation of correctly folded 
proteins, we have identified 68 proteins as novel autoantigens in SLE, and confirmed 11 known 
SLE autoantibody targets. Post-validation meta-analysis found suggestive evidence for a further 
41 autoantigens. The design of microarray used in our study found a large number of novel 
autoantigens in stark contrast to previous proteomic approaches to autoantigen discovery which 
have only identified a handful of new autoantigens [13, 29]. A striking feature of the novel SLE 
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autoantigens found in our study is that many are clearly identifiable as important immune system 
regulators, in multiple cases already implicated in SLE pathogenesis. Thirteen of the 106 novel 
autoantigens have been directly implicated in SLE pathogenesis or genetic susceptibility. This 
helps to confirm the validity of this new protein microarray approach for identification of novel 
autoantibodies. 
 Unsupervised hierarchical clustering of the novel autoantigens revealed four SLE 
subgroups present in both the discovery and validation cohorts, associated with four clusters of 
autoantigens (Figure 3A). The clustering designation of both the SLE subgroups and autoantigen 
clusters was strongly supported by principal component analysis (Figure 4A,B). The most well-
known autoantigens form cluster 1a, which includes TROVE2 (Ro60), SSB (La), the proteasome 
subunit PSME3 (Ki, PA28 gamma) and SMN1, which complexes with Sm and U1-RNP 
autoantigens as part of the spliceosome. Cluster 1b includes known autoantigens HNRNPA2B1, 
PABPC1 and HMGB2. Autoantigens in clusters 1a and 1b are distinguished by a functional 
theme of involvement in RNA processing including mRNA decay (RQCD1), mRNA splicing 
(SMN1), mRNA editing (APOBEC3G, PABPC1, IGF2BP3), nucleocytoplasmic RNA transport 
(Ro60, SSB/La and HNRNPA2B1) and microRNA binding (LIN28A). Other cluster 1b antigens 
are involved in chromatin remodelling and DNA binding. Comparison with ANA and dsDNA 
antibody levels showed that group 1a were strongly ANA positive and group 2 were strongly 
dsDNA positive. Group 1b and 3 showed lower levels of ANA and dsDNA antibodies and 90% 
of the ANA negative individuals were from SLE1b and SLE3. It is important to note that ANA 
and dsDNA positivity was measured on the same samples as used for the microarray assay, to 
allow direct comparison. Although ANA positivity is typically quoted as >95% in SLE 
individuals at or around the time of diagnosis, ANA autoantibodies can become negative over 
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time in >20% of individuals [30]. In a large multicentre study of 446 SLE individuals, of whom 
98% were historically ANA positive, only 71% were ANA positive at the time of study entry 
[31]. It is well established that low titres of ANA can be detected in healthy individuals [26]. 
Thus, cluster 1b and 3 autoantigens are of major clinical importance for aiding diagnosis of SLE 
individuals who are ANA of low titre or intermittently negative and/or anti-dsDNA antibody 
negative. 
Specific autoantibody clusters were associated with significant differences in 
subphenotype. The presence of arthritis was associated with lower cluster 1A autoantibody 
positivity and higher levels of cluster 2 autoantibodies such as PRKRA, consistent with the 
importance of Wnt signalling in synovial biology. Renal involvement was associated with higher 
cluster 1B autoantibodies, specifically IGF2BP3. Another 1B autoantibody HNRNPA2B1 has 
been previously associated with lupus nephritis [32], but showed less strong association than 
IGF2BP3 in our cohort. Certain novel autoantibodies were associated with certain SLE 
manifestations: CARHSP1 positivity showed strong association with thrombocytopenia and 
TWIST2 was associated with oral ulceration. There were differences in pulmonary and 
neurological involvement between autoantibody clusters, however due to the heterogeneous 
nature of pulmonary and neurological manifestations, these associations require validation in 
cohorts with more detailed clinical information and granularity. Overall, the novel autoantibodies 
have potential prognostic utility for predicting specific disease manifestations and organ 
involvement in SLE. 
We used the STRING database to analyse the autoantigen clusters for protein-protein 
interactions (Figure 5). Two key themes emerged: cluster 2 autoantigens centred around SMAD2 
and SMAD5 were linked to TGF-/Wnt/BMP signalling; cluster 3 autoantigens were implicated 
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in TLR/NF-kB signalling, apoptosis regulation, and B and T lymphocyte development. The 
SLE2 subgroup associated with highest positivity for cluster 2 autoantigens showed the highest 
levels of arthritis and Raynaud’s, consistent with TGF-β pathway involvement. Excess TLR7 
activity is linked to development of SLE [33], and we identified a distinct subgroup of SLE 
patients (SLE3) associated with autoantibodies against the TLR adaptor MYD88, NF-κB 
signalling proteins TAK1 and MAP3K14 (NIK), and apoptosis regulators BIRC3 (cIAP-2) and 
ANXA1 (annexin A1) [34]. The demonstration that anti-Ro and anti-La antibodies in SLE sera 
bound apoptotic cell blebs [35] led to the ‘waste disposal hypothesis’, which proposed that 
defective clearance of dying cells is the source of autoantigen exposure [36]. Annexin A1 is 
released by apoptotic neutrophils and promotes phagocytosis of apoptotic neutrophils by 
macrophages [37]. TLR7 is upregulated in SLE neutrophils and primes neutrophils for 
production of neutrophil extracellular traps (NETs), which have been proposed as a source of 
antigen for anti-dsDNA antibody formation [38]. It is conceivable that some cluster 3 antigens 
may originate from neutrophils undergoing NETosis or apoptosis. 
SLE3 cluster autoantigens also included transcription factors and adaptors important for 
regulating lymphocyte development including ZAP70, EGR2, CREB1 and VAV1. Egr-2 
controls T cell self-tolerance and Egr2 deficient mice develop lupus-like autoimmune disease 
[18]. ZAP70 and VAV1, which strongly clustered together, are both recruited to the 
immunological synapse following T cell receptor stimulation, and may reside in membrane 
microdomains leading to inclusion in secreted exosomes [39]. Excess type I interferon activity 
plays an important role in SLE pathogenesis, and several notable interferon pathway genes 
(IRF4, IRF5) were identified as autoantigens. 
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The clustering of antigens into functional groups hints at different underlying pathogenic 
mechanisms defining SLE subgroups. If the new classes of autoantibodies represent different 
underlying pathogenic mechanisms, this would have important clinical ramifications, with the 
prediction that the SLE subgroups defined by this study might require different treatment 
strategies. For example, patients with NF-κB and B cell differentiation genes as antigens may be 
a subgroup which are more likely to respond to B cell therapies (e.g. Rituximab, Belimumab), 
while patients with TGF-β/Wnt signalling pathways may be at risk of fibrotic manifestations 
overlapping with systemic sclerosis, and might respond to non-B cell specific therapies (e.g. 
cyclophosphamide).  
This study has a number of limitations including: the single timepoint for sample 
collection; lack of clinical information on disease activity at the time of sample collection; 
incomplete information on organ manifestations (e.g. pulmonary and neurological) and anti-
phospholipid syndrome status; and absence of HEp-2 ANA assay as a comparator. ANA ELISA 
was employed in this study since it is less prone to operator-dependent subjectivity than the 
standard HEp-2 ANA fluorescence assay, however HEp-2 ANA is more sensitive than ELISA. 
Thus, future studies to further investigate which of these novel autoantibodies are useful for 
prognosis, therapeutic stratification or monitoring disease activity alongside anti-dsDNA 
antibodies, will necessitate longitudinal, prospective studies to collect serial samples alongside 
more detailed clinical information on type of organ involvement and neurological features. HEp-
2 ANA assay should also be included in the comparison. Since some autoantibodies, such as 
cardiolipin antibodies [40], can be triggered by acute infections, sera from an infectious diseases 
cohort should be compared with the SLE cohort. Following the identification of TGF-β pathway 
autoantigens, the confounding disease cohort should include a larger cohort of other connective 
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tissue diseases including a large systemic sclerosis cohort with detailed clinical information on 
systemic sclerosis type (limited or diffuse) and patterns of organ involvement (interstitial lung 
disease, Raynaud’s manifestations etc). 
 We identified a 17-autoantibody autoantibody biomarker panel which showed improved 
sensitivity and specificity for diagnosis of SLE in comparison to standard ANA and anti-dsDNA 
assays (Figure 6A,B). However, this binomial model, which was trained for simple 
discrimination of SLE patients from controls, was outperformed by a multinomial regression 26-
autoantibody model trained to discriminate four clusters of SLE individuals by penalised mixture 
discriminant analysis (MDA). The MDA model, by accounting for clustering of SLE individuals, 
showed enhanced diagnostic performance in the validation cohort compared to conventional 
ANA and dsDNA assays. The use of a repertoire of autoantibodies for SLE diagnosis has 
parallels with the peptide libraries employed by anti-CCP diagnostic assays for RA, and the 26-
autoantibody biomarker panel demonstrates comparable sensitivity/specificity for SLE diagnosis 
to anti-CCP assays in RA [41]. 
In summary, using improved protein microarray technology with attention to optimal 
protein folding and synthesis, we have identified a large number of novel SLE autoantigens. Our 
study suggests that SLE can be subgrouped by molecular signature through four distinct 
autoantibody patterns. We propose that each SLE subgroup may have diverse pathogenic and/or 
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Figure 1. Novel autoantigens identified by protein microarray in Systemic Lupus 
Erythematosus (SLE) 
(A) Novel protein microarray technology used BCCP folding tag to improve protein folding 
conformation of array-bound proteins. (B) Volcano plot of autoantigens in the Discovery cohort 
displaying each microarray autoantigen as a single point with P value on the y-axis versus log2 
fold change in antibody levels between SLE and matched controls on the x-axis. P values were 
calculated using a linear regression model adjusting for cohort, sex, age and ethnicity. Blue 
points signify FDR-corrected Ptrain<0.01. (C) Volcano plot of autoantigens validated in the 
validation cohort. Red points show autoantigens validated in both cohorts (FDR-corrected Ptrain 
and Ptest<0.01), blue points show autoantigens found in Discovery cohort but not replicated in 
Validation cohort. Red points show autoantigens validated in both cohorts, blue points show 
autoantigens with FDRmeta<0.01. (D & E) Tukey boxplots of median normalised IgG binding 
data showing IgG autoantibody reactivity against specific antigens on the protein microarray in 
the discovery cohort (Control1, n=188; SLE1, n=186) and the validation cohort (Control2, n=92; 
SLE2, n=91). (D) Top four previously identified autoantigens confirming validation of lesser 
known antigens PABPC1 and HMGB2. (E) Top four novel autoantigens identified by 
microarray. Box plots show median, upper and lower quartiles, with whiskers denoting maximal 
and minimal data within 1.5 × interquartile range (IQR). Dark blue dots represent antibody 
positivity defined as >2 SD of control population. Confounding group includes individuals with 




Figure 2. Hierarchy of autoantibody positivity in SLE individuals 
(A) Autoantigens ranked by positivity in SLE patients in both Discovery and Validation cohorts. 
P values were calculated by Fisher test with FDR correction for multiple testing. FDR-corrected 
P<0.05 in both discovery and validation cohorts was considered significant. (B) Distribution 
histogram showing total number of positive autoantibodies for each individual showing that sera 
from SLE patients can recognise over 60 discrete autoantigens. 
 
Figure 3. Hierarchical clustering identifies four SLE autoantibody subgroups 
(A) Heatmap of unsupervised hierarchical clustering of 79 validated autoantibody levels in SLE 
individuals from the discovery cohort (n=186) and validation cohort (n=91), using correlation as 
distance metric and Ward’s clustering method. Rows were clustered based on the discovery 
cohort. Autoantibody levels were Z score normalised against control population mean and SD, 
with Z scores >2 corresponding to positive autoantibody levels. Autoantibodies cluster into four 
major clusters, with four matching clusters SLE1a, SLE1b, SLE2 and SLE3 identified in SLE 
individuals and the four patient clusters were observed in both the discovery and validation 
cohorts. (B) Correlation plot of Pearson r values shows significant cross-correlation of 
autoantibodies within each cluster. 
 
Figure 4. Autoantibody cluster-defined SLE subgroups show different disease 
characteristics 
(A) Principal component analysis of 79 autoantibody levels in SLE individuals and controls. 
Principal component (PC) scores for PC1-3 showing clusters of SLE individuals identified by 
hierarchical clustering. Ellipsoids show 95% confidence intervals. (B) PC loading scores for 
25 
 
PC2, PC3 and PC4 showing clustering of autoantigens identified by hierarchical clustering. (C) 
Anti-nuclear and anti-double-stranded DNA antibody results according to SLE cluster groups 
SLE1a, SLE1b, SLE2 and SLE3. ANA and dsDNA sera levels were measured by ELISA, and 
are not based on patient clinical records. Statistical analysis by Kruskal-Wallis test. (D) 
Comparison of SLE subgroups among ANA and dsDNA negative individuals, showing that 
ANA negative individuals are predominantly from subgroups SLE1b and SLE3. (E) 
Subphenotype comparison of autoantibody clusters. Heatmap represents subphenotype fold 
change for mean autoantibody levels for each autoantibody cluster. P values calculated for 
interaction between autoantibody cluster and subphenotype by two-way ANOVA. *P<0.05 for 
pairwise comparisons for presence/absence of subphenotype. (F) Positivity of individual 
autoantibodies across subphenotypes. (G) Differential usage of medications in SLE clusters. 
Statistical analysis in D, F, G by Fisher’s exact test. 
 
Figure 5. SLE autoantigen clusters demonstrate functional protein-protein interaction 
networks 
(A & B) Protein-protein interaction networks were derived from STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins) database and plotted using Cytoscape for (A) cluster 2 
and (B) cluster 3 autoantigens. Line thickness represents strength of interaction confidence. 
Predicted nodes are shown in orange. (C) Phylogenetic tree of autoantigens summarising key 




Figure 6. Improved diagnostic performance of 26-autoantibody biomarker panel 
(A-B) Diagnostic biomarker panels were derived by elastic net penalised logistic regression 
using binomial model (control, SLE) or multinomial model (control, 4 SLE clusters) for variable 
selection. The optimal model was the 26-autoantibody panel selected by multinomial elastic net 
logistic regression and trained using penalised mixture discriminant analysis (MDA) employing 
one control cluster and four SLE clusters. All models were trained exclusively on the Discovery 
cohort and tested on the Validation test cohort. (A) Receiver operating characteristic (ROC) 
curves for Validation cohort are shown for MDA and elastic net derived biomarker panels 
compared with ANA, dsDNA and combined ANA + dsDNA model. (B) Table of area under 
curve (AUC), sensitivity and specificity of biomarker panels (MDA, binomial elastic net 
regression) compared to ANA, dsDNA and ANA + dsDNA model. (C) Heatmap of Z scores of 
mean autoantibody levels in each SLE subgroup for 26-autoantibody biomarker panel. Statistical 






Movie S1. 3D plot of principal component scores for SLE individuals and controls 
Three-dimensional plot of principal component scores 1-3 for SLE individuals and controls (grey 
spheres). SLE individuals are coloured according to subgroup SLE1a (red), SLE1b (purple), 
SLE2 (green), SLE3 (blue) as determined by hierarchical clustering. 
 
Movie S2. 3D plot of principal component loading scores for SLE autoantigens 
Three-dimensional plot of principal component loading scores for SLE autoantigens, along axes 
PC2, PC3 and PC4. Autoantigens are coloured according to antigen cluster 1a (red), cluster 1b 
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MDA Elastic net ANA + dsDNA ANA dsDNA
(26 Ab model) (17 Ab model)
AUC 0.860 0.773 0.822 0.806 0.618
AUC 95% CI 0.813 - 0.907 0.704 - 0.842 0.766 - 0.878 0.748 - 0.865 0.538 - 0.697
Sensitivity (specificity 85%) 71.4% 65.9% 65.5% 67.0% 44.3%
Sensitivity (specificity 90%) 67.0% 59.3% 47.8% 37.0% 38.6%
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